Résumé
Migraine is a recurrent throbbing or pulsing headache with moderate to severe pain intensity. The pain is often one side of the head with nausea and weakness symptoms. Around 12 percent of Americans, 9 percent of Asians experiences migraine and the prevalence is highest among South Koreans (22.3%). The outcome of chronic migraine treatment can be quite disheartening, causing patients to feel out of options who have tried multiple treatments with no results. Poor efficacy, tolerability and safety of migraine preventive therapy in clinical practice lead to poor compliance and failure of therapy. The mean change in number or frequency of headache is considered as the outcome measure of migraine prevention therapy. Upon comparing all migraine prevention therapy, the Fremanezumab, Eptinezumab, Galcanezumab and Erenumab were considered as the front runner in controlling the severity and frequency of migraine. Among these drugs, Erenumab was most effective in controlling the frequency of migraine episodes as it produces more than 50 percent reduction in the mean number of monthly migraine days (MMD) over week 9-week 12. In addition to drug therapy, adequate rest, balanced diet, yoga and meditation will help patients to get rid of migraine severity. A multi-dimensional approach is essential for better control over migraine symptoms.
Résumé
Background: Primary headache disorders are among the most ubiquitous disorders affecting people worldwide. Migraine headache is one of the commonest syndromes of primary headache. There are few studies regarding clinical profile of migraine and migraine triggers in India. The objective this study was to study the gender, age distribution, frequency, severity of migraine attacks and other associated symptoms in patients presenting with migraine. To study in detail about triggers of migraine in present study population.Methods: About 222 patients who presented with history suggestive of migraine with or without aura defined according to International classification of headache disorders 2, fulfilling the study criteria were included. The study duration was fifteen months from March 2017 to May 2018. Details were collected using a proforma.Results: In this study, incidence of Migraine is higher in females (169,76%) than males (53, 24%). Majority of migraine patients were between age group of 18-29 years constituting about 77 patients (34.65%). Frequency of migraine more commonly observed was 3-4 per month was observed in 64 patients (29%) and chronic migraine was seen in 19 patients (8.4%). Migraine without aura is most common type observed in this study. Many patients had more than one trigger. More common triggers identified were sun exposure (85, 38.3%), sleep deprivation (83, 37.4%), stress (84, 37.8%) and travel (80, 36%).Conclusions: Migraine is more common in females than males with majority being in between age group of 18-29 years. Many had frequency of 3-4 episodes per month. Most had more than one trigger.
Résumé
Phonophobia and hyperacusis are two separate but closely related symptoms that are often mistakenly used in clinical practice as the same entity. Here we present a case report to highlight the distinguishing features of both and discuss the steps of management in these conditions. It is vital for the attending doctors to recognise hyperacusis and phonophobia as different entities to manage them successfully.